21世纪经济报道记者韩利明上海报道随着“首款国产新冠中和抗体药物”停产,尚未有其他商业化产品的腾盛博药(02137.HK),日前发布2024年业绩显示,报告期内公司无营业收入,仅录得其他收入1.41亿元;年内亏损5.12亿元,与截至2023年底的1.84亿元相比,扩大177.9%。综合年报及业绩说明会,“节流”已成为腾盛博药的关键词之一。公司董事会主席兼首席执行官洪志表示,“根据战略优先级,公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.